[Corrigendum] HHLA2 is a novel prognostic predictor and potential therapeutic target in malignant glioma
Affiliations: Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China
- Published online on: December 27, 2022 https://doi.org/10.3892/or.2022.8473
- Article Number: 36
Copyright : © Qi et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].
This article is mentioned in:
Oncol Rep 42: [Related article:] 2309–2322, 2019; DOI: 10.3892/or.2019.7343
Following the publication of this article, an interested reader drew to the authors' attention that, in Fig. 1F on p. 2311 showing a representative high-grade glioma specimen, the data were either duplicated or overlapping with the data featured in Fig. 1D, which showed a low-grade glioma specimen. After having consulted their original data, the authors have realized that the data for Fig. 1D were inadvertently selected incorrectly.
Representative specimens exhibiting HHLA2 IHC labeling pattern in normal brain, low-grade glioma, and high-grade glioma. HHLA2 IHC are presented. (A and B) Normal brain. (C and D) Low-grade glioma. (E and F) High-grade glioma. Scale bar, 100 and 25 µm, respectively.
The corrected version of Fig. 1, now showing the correct data for the high-magnification high-grade glioma specimen in Fig. 1F, is shown on the next page. The authors sincerely apologize for the error that was introduced during the preparation of this figure, thank the Editor of Oncology Reports for granting them the opportunity to publish a Corrigendum, and are grateful to the reader for alerting them to this issue. The authors also regret any inconvenience that this mistake may have caused.